Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02049541 |
|
Recruitment Status :
Completed
First Posted : January 30, 2014
Last Update Posted : June 30, 2022
|
Sponsor:
Kami Maddocks, MD
Collaborator:
Novartis
Information provided by (Responsible Party):
Kami Maddocks, MD, Ohio State University Comprehensive Cancer Center
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Completed |
|---|---|
| Actual Primary Completion Date : | September 12, 2018 |
| Actual Study Completion Date : | April 9, 2019 |